Title:
CANCER STEM CELL INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2019/069891
Kind Code:
A1
Abstract:
To provide a novel medicine for suppressing cancer stem cells. An inhibitor of mitochondria in cancer stem cells which comprises a 2-nitroimidazole derivative as an active ingredient.
Inventors:
SAYA HIDEYUKI (JP)
SAMPETREAN OLTEA (JP)
KOIKE NAOYOSHI (JP)
KUBOTA NOBUO (JP)
SAMPETREAN OLTEA (JP)
KOIKE NAOYOSHI (JP)
KUBOTA NOBUO (JP)
Application Number:
PCT/JP2018/036792
Publication Date:
April 11, 2019
Filing Date:
October 02, 2018
Export Citation:
Assignee:
UNIV KEIO (JP)
POLA PHARMA INC (JP)
POLA PHARMA INC (JP)
International Classes:
A61K31/4168; A61K31/4172; A61P35/00; A61P35/04; C07D233/91
Domestic Patent References:
| WO1994014778A1 | 1994-07-07 |
Foreign References:
| JP2005027515A | 2005-02-03 | |||
| JP2017031059A | 2017-02-09 | |||
| JPH0977667A | 1997-03-25 | |||
| JP2005027515A | 2005-02-03 | |||
| JP2007326814A | 2007-12-20 | |||
| JP2007302610A | 2007-11-22 | |||
| JPH08291064A | 1996-11-05 | |||
| JPH03223258A | 1991-10-02 |
Other References:
YOON, CHANGHWAN ET AL.: "Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-lalpha inhibition, and hypoxia-activated chemotherapy", ONCOTARGET, vol. 7, no. 28, 21 June 2016 (2016-06-21), pages 42844 - 42858, XP055591793, ISSN: 1949-2553
LI, QUHUAN ET AL.: "Hypoxia-activated cytotoxicity of benznidazole against clonogenic tumor cells", CANCER BIOLOGY & THERAPY, vol. 17, no. 12, 28 November 2016 (2016-11-28), pages 1266 - 1273, XP055591806, ISSN: 1538-4047
BENITO, JULIANA ET AL.: "Hypoxia-activated prodrug TH -302 targets hypoxic bone marrow niches in pre- clinical leukemia models", CLINICAL CANCER RESEARCH, vol. 22, no. 7, 1 April 2016 (2016-04-01), pages 1687 - 1698, XP055683135, ISSN: 1078-0432, DOI: :10.1158/1078-0432.CCR-14-3378
SHIDENG BAO, NATURE, 2006
HEDDLESTON JM., CELL CYCLE, vol. 8, no. 20, 2009, pages 3274 - 3284
JUSTIN D. LATHIA, PLOS ONE, vol. 6, 2011, pages e24807
MATSUOKA H., ONCOL. REP., vol. 1, 2000, pages 23 - 26
ELSA QUINTANA, NATURE, vol. 456, no. 7222, 4 December 2008 (2008-12-04), pages 593 - 598
SAMPETREAN O., NEOPLASIA, vol. 13, no. 9, 2011, pages 784 - 791
Y XIE, CELL DEATH AND DIFFERENTIATION, vol. 23, 2016, pages 369 - 379
LI, QUHUAN ET AL.: "Hypoxia-activated cytotoxicity of benznidazole against clonogenic tumor cells", CANCER BIOLOGY & THERAPY, vol. 17, no. 12, 28 November 2016 (2016-11-28), pages 1266 - 1273, XP055591806, ISSN: 1538-4047
BENITO, JULIANA ET AL.: "Hypoxia-activated prodrug TH -302 targets hypoxic bone marrow niches in pre- clinical leukemia models", CLINICAL CANCER RESEARCH, vol. 22, no. 7, 1 April 2016 (2016-04-01), pages 1687 - 1698, XP055683135, ISSN: 1078-0432, DOI: :10.1158/1078-0432.CCR-14-3378
SHIDENG BAO, NATURE, 2006
HEDDLESTON JM., CELL CYCLE, vol. 8, no. 20, 2009, pages 3274 - 3284
JUSTIN D. LATHIA, PLOS ONE, vol. 6, 2011, pages e24807
MATSUOKA H., ONCOL. REP., vol. 1, 2000, pages 23 - 26
ELSA QUINTANA, NATURE, vol. 456, no. 7222, 4 December 2008 (2008-12-04), pages 593 - 598
SAMPETREAN O., NEOPLASIA, vol. 13, no. 9, 2011, pages 784 - 791
Y XIE, CELL DEATH AND DIFFERENTIATION, vol. 23, 2016, pages 369 - 379
Attorney, Agent or Firm:
THE PATENT CORPORATE BODY ARUGA PATENT OFFICE (JP)
Download PDF: